Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene Chapman

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|May 26, 2010
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseasesVicente E Torres, Alessandra Boletta, Arlene Chapman, et al.
Clinical Biochemistry|December 5, 2022
Measuring copeptin, a surrogate for vasopressin in patients with hypertension - Can it identify those who are volume Responsive?Ronstan Lobo, John C Lieske, Leslie J Donato, et al.
Plos One|January 30, 2014
Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environmentKyoungmi Kim, Christine Mall, Sandra L Taylor, et al.
Kidney360|December 11, 2020
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney DiseaseLaura Grau, Berenice Gitomer, Bryan McNair, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2024
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD TrialsElaine Ku, Timothy P Copeland, Charles E McCulloch, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 19, 2025
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney DiseaseKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Kidney Medicine|August 17, 2021
Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) StudiesKristen L Nowak, Kaleigh Murray, Zhiying You, et al.
Journal of the American Heart Association|February 26, 2018
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-BlockersMohamed H Shahin, Daniela J Conrado, Daniel Gonzalez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 11, 2026
Renal blood flow and progression to kidney failure in ADPKDKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Pharmacotherapy|October 2, 2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) studySteven M Smith, Shawn D Anderson, Sheron Wen, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Clinical Journal of the American Society of Nephrology : CJASN|May 26, 2010
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseasesVicente E Torres, Alessandra Boletta, Arlene Chapman, et al.
Clinical Biochemistry|December 5, 2022
Measuring copeptin, a surrogate for vasopressin in patients with hypertension - Can it identify those who are volume Responsive?Ronstan Lobo, John C Lieske, Leslie J Donato, et al.
Plos One|January 30, 2014
Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environmentKyoungmi Kim, Christine Mall, Sandra L Taylor, et al.
Kidney360|December 11, 2020
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney DiseaseLaura Grau, Berenice Gitomer, Bryan McNair, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 18, 2024
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD TrialsElaine Ku, Timothy P Copeland, Charles E McCulloch, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 19, 2025
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney DiseaseKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Kidney Medicine|August 17, 2021
Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) StudiesKristen L Nowak, Kaleigh Murray, Zhiying You, et al.
Journal of the American Heart Association|February 26, 2018
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-BlockersMohamed H Shahin, Daniela J Conrado, Daniel Gonzalez, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 11, 2026
Renal blood flow and progression to kidney failure in ADPKDKristen L Nowak, Timothy P Copeland, Elaine Ku, et al.
Pharmacotherapy|October 2, 2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) studySteven M Smith, Shawn D Anderson, Sheron Wen, et al.
Pageof 5